Celmatix, a biotechnology company focused on helping physicians guide patients to treatments that maximize their personal reproductive potential, announced today six research presentations at the annual meeting of the American Society for Reproductive Medicine (ASRM), being held October 12-17 in Boston. Among the data presented was a new study suggesting that up to 25 percent of patients may be discontinuing assisted reproductive therapies such as in vitro fertilization (IVF) early, while they still have a good chance of having a baby. The clinical study, which was performed on a dataset of over 6,000 patients from study co-authors Reproductive Medicine Associates of New York, showed that 68 percent of women conceived within two cycles. For those who did not conceive in that time frame and chose to discontinue treatment, the data suggested that more than half (60 percent) would have become pregnant if they had proceeded with an additional two treatment cycles. Other Celmatix findings being presented at ASRM include data on genetic markers related to currently unexplained female infertility and IVF success; factors correlated with higher risk of ectopic pregnancy; and an analytical model that predicts the estimated number of cycles needed by a particular couple to achieve live birth using various fertility treatments.